AU2004238038A1 - Bicalutamide forms, compositions, and processes thereof - Google Patents

Bicalutamide forms, compositions, and processes thereof Download PDF

Info

Publication number
AU2004238038A1
AU2004238038A1 AU2004238038A AU2004238038A AU2004238038A1 AU 2004238038 A1 AU2004238038 A1 AU 2004238038A1 AU 2004238038 A AU2004238038 A AU 2004238038A AU 2004238038 A AU2004238038 A AU 2004238038A AU 2004238038 A1 AU2004238038 A1 AU 2004238038A1
Authority
AU
Australia
Prior art keywords
bicalutamide
granulate
dosage form
pharmaceutical composition
micronized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004238038A
Other languages
English (en)
Inventor
Joan Cucala Escoi
Arturo Siles Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of AU2004238038A1 publication Critical patent/AU2004238038A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004238038A 2003-05-14 2004-05-13 Bicalutamide forms, compositions, and processes thereof Abandoned AU2004238038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47022403P 2003-05-14 2003-05-14
US60/470,224 2003-05-14
PCT/EP2004/005189 WO2004100944A1 (en) 2003-05-14 2004-05-13 Bicalutamide forms, compositions, and processes thereof

Publications (1)

Publication Number Publication Date
AU2004238038A1 true AU2004238038A1 (en) 2004-11-25

Family

ID=33452382

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004238038A Abandoned AU2004238038A1 (en) 2003-05-14 2004-05-13 Bicalutamide forms, compositions, and processes thereof

Country Status (9)

Country Link
US (1) US20050008691A1 (enExample)
EP (1) EP1622604A1 (enExample)
JP (1) JP2006528221A (enExample)
AU (1) AU2004238038A1 (enExample)
CA (1) CA2525318A1 (enExample)
FI (1) FI7526U1 (enExample)
NO (1) NO20055943L (enExample)
WO (1) WO2004100944A1 (enExample)
ZA (1) ZA200509152B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005260816B2 (en) * 2004-07-14 2010-12-16 Sumitomo Chemical Company, Limited Method of crystallizing bicalutamide

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms
WO2006103689A1 (en) * 2005-03-29 2006-10-05 Usv Limited Process for preparation of bicalutamide
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
CA2614468A1 (en) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CZ299577B6 (cs) * 2005-12-20 2008-09-03 Interpharma Praha, A. S. Zpusob výroby vysoce cistého 4-kyano-3-trifluoromethyl-N-(3-p-fluorfenylsulfonyl-2-hydroxy-2-methylpropionyl) anilinu
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
WO2008068770A2 (en) * 2006-07-07 2008-06-12 Panacea Biotec Limited Pharmaceutical composition containing bicalutamide and a method for its use
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
AU2007295179B2 (en) * 2006-09-15 2013-05-30 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
AU2007295178B2 (en) * 2006-09-15 2013-04-18 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
GB0702826D0 (en) * 2007-02-14 2007-03-28 Pliva Istrazivanje I Razvoj D Preparation and composition of solid dosage form containing Bicalutamide
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN118105392A (zh) * 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
WO1995019770A1 (en) * 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
HU223950B1 (hu) 1999-06-10 2005-03-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására
ATE307571T1 (de) * 2001-02-27 2005-11-15 Pharmazeutische formulierung enthaltend bicalutamid
CA2443040A1 (en) * 2001-04-02 2002-10-17 Nicola Frances Bateman Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
US6458769B1 (en) * 2001-06-25 2002-10-01 Astrazeneca Ab Amorphous compound
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005260816B2 (en) * 2004-07-14 2010-12-16 Sumitomo Chemical Company, Limited Method of crystallizing bicalutamide

Also Published As

Publication number Publication date
US20050008691A1 (en) 2005-01-13
CA2525318A1 (en) 2004-11-25
FI7526U1 (fi) 2007-06-12
NO20055943L (no) 2006-01-25
WO2004100944A1 (en) 2004-11-25
JP2006528221A (ja) 2006-12-14
FIU20060440U0 (fi) 2006-10-25
ZA200509152B (en) 2007-04-25
EP1622604A1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
US20050008691A1 (en) Bicalutamide compositions
US6511681B2 (en) Aqueous solubility pharmaceutical formulations
EP2442799B2 (en) Solid pharmaceutical composition comprising rivaroxaban
Roblegg et al. Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion
EP2217214B1 (en) Pharmaceutical formulation comprising ezetimibe
US20190125725A1 (en) Pharmaceutical compositions comprising brivaracetam
PL206595B1 (pl) Preparat farmaceutyczny w postaci mikrosfer, sposób wytwarzania tego preparatu oraz farmaceutyczna postać dawkowania zawierająca ten preparat
WO2009135646A2 (en) Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
KR100253046B1 (ko) 고함량 이부프로펜 응집물의 제조방법(High content ibuprofen agglomerates and process to prepare them)
WO2008149338A2 (en) Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
EP3003277B1 (en) Process for the preparation of a pharmaceutical composition comprising rivaroxaban
EP1487429A2 (en) Compositions of venlafaxine base
EP2050436A1 (en) Pharmaceutical composition containing dutasteride
CZ303694B6 (cs) Prípravek nesteroidního protizánetlivého léciva obsahující granulární a extragranulární kompozici a zpusob jeho prípravy
JPH11246404A (ja) 吸収を改善した医薬組成物
WO2007073389A1 (en) Compressed solid dosage forms with drugs of low solubility and process for making the same
WO2014009817A1 (en) Pharmaceutical composition of febuxostat
WO2025046606A1 (en) Granules of mavacamten for oral administration
JP2025526729A (ja) ナポラフェニブを含む非晶質固体分散体
CZ2005546A3 (cs) Zpusob výroby jemne krystalické smesi obsahující nesteroidní protizánetlivé lécivo, jemne krystalická smes pripravitelná tímto zpusobem a pevný farmaceutický prostredek tuto smes obsahující
JP2007513068A (ja) Ｌｔｂ４−アンタゴニストを含む医薬製剤、並びにその調製方法及びその使用
JP2007131587A (ja) キノリノン誘導体を有効成分とする医薬組成物、及びその製造方法
WO2007007183A2 (en) Compositions of antiviral compound
WO2004004717A1 (en) Pharmaceutical composition comprising (s)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1h-indole

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application